// App-Quantinova.ai

THU0213 : UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 84 WEEKS FROM THE SELECT-MONOTHERAPY STUDY

Researchers

Presenter

  • J. S. Smolen

Principal Investigators

  • P. Emery

  • W. Rigby

  • Y. Tanaka

  • J. Ignacio Vargas

  • N. Damjanov

  • M. Jain

  • Y. Song

  • N. Khan

  • J. J. Enejosa

  • S. B. Cohen

Medical Centers

  • Medical University of Vienna, Vienna, Austria

  • University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom

  • Dartmouth College, Lebanon, United States of America

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Quantum Research, Puerto Varas, Chile

  • University of Belgrade School of Medicine, Institute of Epidemiology, Belgrade, Serbia

  • Great Lakes Clinical Trials, Chicago, IL, United States of America

  • Metroplex Clinical Research Center, Dallas, United States

Locations

  • Austria

  • United Kingdom

  • United States

  • Japan

  • Chile

  • Serbia

Companies

  • N/A

Study Components

Therapeutic Area

  • Peripheral Nervous System

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Charcot-Marie-Tooth disease, X-linked dominant, 1

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • Methotrexate

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved